---
title: "Boston Scientific Corp 1Q 2026: Revenue $5.2B, EPS $0.9— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284907701.md"
description: "Boston Scientific Corp reported a strong first quarter for 2026, with revenue reaching $5.2 billion and diluted EPS of $0.9, marking an 11.6% increase year-over-year. Key drivers included growth in Electrophysiology, Interventional Cardiology, and Vascular Therapies. The company also improved its gross margin to 69.4% and engaged in strategic activities such as acquiring Nalu and announcing a deal with Penumbra, pending FTC review. Net income nearly doubled to $1.34 billion compared to the previous year."
datetime: "2026-05-01T14:01:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284907701.md)
  - [en](https://longbridge.com/en/news/284907701.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284907701.md)
---

# Boston Scientific Corp 1Q 2026: Revenue $5.2B, EPS $0.9— 10-Q Summary

Boston Scientific Corp reported first-quarter 2026 results with revenue rising to $5.2B and diluted EPS of $0.9, driven by broad commercial strength across key franchises and improved margins versus the year-ago quarter.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$5.2B

$4.66B

11.6%

Net income²

$1.34B

$674M

99%

Diluted EPS³

$0.9

$0.45

100%

_¹ Reported as “Net sales”. ² Reported as “Net income (loss) attributable to Boston Scientific common stockholders”. ³ Reported as “Net income (loss) per common share — diluted”._

**Business Highlights**

-   Revenue growth of 11.6% (9.4% operational) was led by Electrophysiology, Interventional Cardiology and Vascular Therapies.
-   Key franchises including Farapulse PFA, WATCHMAN, AGENT DCB, Intracept and Nalu drove higher sales and market adoption.
-   Gross margin improved to 69.4%, supported by a higher‑margin product mix and reduced acquisition step‑up impacts.
-   Strategic activity included the acquisition of Nalu, announcement of the Penumbra deal (subject to FTC review) and completion of major restructuring actions.

Original SEC Filing: BOSTON SCIENTIFIC CORP \[ BSX \] - 10-Q - May. 01, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [PEN.US](https://longbridge.com/en/quote/PEN.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [BSX.US](https://longbridge.com/en/quote/BSX.US.md)

## Related News & Research

- [3,550 Shares in Penumbra, Inc. $PEN Bought by Radnor Capital Management LLC](https://longbridge.com/en/news/286893569.md)
- [BUZZ-Boston Scientific shares rise on $2 bln accelerated buyback](https://longbridge.com/en/news/286801797.md)
- [Boston Scientific Targets Growing Aortic Stenosis Market With $1.5 Billion Deal](https://longbridge.com/en/news/286808399.md)
- [Edwards Lifesciences CVP, Strategy/Corp Development Sold Shares Worth Over $1.4M](https://longbridge.com/en/news/286822028.md)
- [Shutterstock Reaches $35 Million FTC Subscription Settlement](https://longbridge.com/en/news/286474120.md)